Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

A 68-year-old man is hospitalized for an acute right lower extremity deep vein thrombosis. His medical history is significant for hypertension, type 2 diabetes mellitus, and end-stage renal disease on hemodialysis. On admission, he was started on a continuous intravenous unfractionated heparin infusion. On hospital day 4, routine morning laboratory studies reveal a platelet count of 85,000/mm385,000/mm^3, representing a significant decline from his baseline of 210,000/mm3210,000/mm^3 on admission. He is hemodynamically stable, his right leg swelling is unchanged, and there is no evidence of active bleeding. A serotonin release assay is ordered, but the clinical suspicion for heparin-induced thrombocytopenia is high. The heparin infusion is immediately discontinued. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Initiate argatroban infusionCevap
  2. B
    Initiate fondaparinux subcutaneous injection
  3. C
    Initiate warfarin oral therapy
  4. D
    Administer a platelet transfusion
  5. E
    Withhold further anticoagulation until the serotonin release assay results return

Cevap

The most appropriate next step is to initiate an argatroban infusion.
The correct answer is to initiate an argatroban infusion. This patient presents with a classic clinical picture of heparin-induced thrombocytopenia (HIT), defined by a >50%>50\% drop in platelet count shortly after starting heparin therapy. HIT is a severe immune-mediated adverse drug reaction caused by IgG antibodies targeting platelet factor 4 (PF4)-heparin complexes, resulting in widespread platelet activation and a severely prothrombotic state. The first step in management is the immediate cessation of all heparin products. However, because the patient is at extremely high risk for life-threatening thrombotic events (and already has a deep vein thrombosis), alternative non-heparin anticoagulation must be started immediately. Argatroban, a direct thrombin inhibitor, is primarily metabolized and cleared by the liver. It does not require dose adjustments in patients with severe chronic kidney disease or end-stage renal disease (ESRD), making it the safest and most appropriate choice in this specific clinical scenario.

Adım Adım Çözüm

1
Diagnose the acute complication based on the clinical presentation.
The patient's platelet count dropped by more than 50% within 4 days of heparin exposure, which strongly suggests heparin-induced thrombocytopenia (HIT).
Recognizing the 4T score criteria for HIT is necessary to halt the offending agent and prevent catastrophic thrombosis.
2
Identify the immediate necessary intervention for this condition.
All heparin products must be immediately discontinued, and an alternative non-heparin anticoagulant must be started.
HIT is a highly prothrombotic state. Stopping heparin is not enough; the patient must be actively anticoagulated to treat the existing deep vein thrombosis and prevent new clots.
3
Select the appropriate pharmacologic agent considering the patient's comorbidities.
Argatroban is chosen over other alternatives like fondaparinux or bivalirudin.
The patient has end-stage renal disease. Argatroban is hepatically cleared and safe for use in severe renal impairment, whereas fondaparinux is renally cleared and strictly contraindicated.

Anahtar Kavram

The management of highly suspected heparin-induced thrombocytopenia (HIT) requires immediate cessation of heparin and initiation of a non-heparin anticoagulant. In patients with severe renal impairment, hepatically cleared argatroban is the preferred agent.

Alternatif Yöntem

While argatroban is widely preferred, bivalirudin is another direct thrombin inhibitor that can be used in HIT; however, it requires careful dose adjustment in renal failure as it is partially enzymatically cleaved and partially renally excreted.
Tahmini Süre:1m 15s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru